Resources

Type of publications
Regions
Diseases

5192 results found

2024 ∙ Liao, X. Lin, M. Yang, L. Cheung, K. Zhang, Q. Li, Y. Hao, C. Wang, H. H. Gao, Y. Zhang, D. D. Molassiotis, A. Siu, G. K. H. Man Leung, A. Y. Xie, Y. J.

Community engagement in vaccination promotion: A systematic review and meta-analysis

  • All age groups
  • COVID-19
  • Acceptance
Methodological quality (AMSTAR 2):
Not applicable
2024 ∙ Xie, Y. J. Liao, X. Lin, M. Yang, L. Cheung, K. Zhang, Q. Li, Y. Hao, C. Wang, H. H. Gao, Y. Zhang, D. Molassiotis, A. Siu, G. K. H. Leung, A. Y. M.

Community Engagement in Vaccination Promotion: Systematic Review and Meta-Analysis

  • All age groups
  • Acceptance
Methodological quality (AMSTAR 2):
Not applicable
2024 ∙ Kavikondala, S. Haeussler, K. Wang, X. Bausch-Jurken, M. T. Nassim, M. Mishra, N. K. Malmenäs, M. Sharma, P. Van de Velde, N. Green, N. Beck, E.

Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines Among Older Adults: Systematic Literature Review and Meta-Analysis Using the GRADE Framework

  • Adults
  • Older adults
  • COVID-19
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Low
2024 ∙ Kim, J. Choe, Y. J. Park, J. Cho, J. Cheong, C. Oh, J. K. Park, M. Shim, E. Yu, S. Y.

Comparative Effects of Bivalent, Quadrivalent, and Nonavalent Human Papillomavirus Vaccines in The Prevention of Genotype-Specific Infection: A Systematic Review and Network Meta-Analysis

  • Adolescents
  • Adults
  • Human papillomavirus (HPV)
  • Efficacy/effectiveness
  • Administration
Methodological quality (AMSTAR 2):
Critically low
2024 ∙ Wu, X. Xu, K. Zhan, P. Liu, H. Zhang, F. Song, Y. Lv, T.

Comparative efficacy and safety of COVID-19 vaccines in phase III trials: a network meta-analysis

  • Adults
  • Older adults
  • COVID-19
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2024 ∙ Omidi, F. Rahmannia, M. Khalili, F. Shahidi Bonjar, A. H. Nasiri, M. J.

Comparing higher-dose and single standard-dose influenza vaccines in preventing cardiovascular events: a meta-analysis with 68,713 patients

  • All age groups
  • Influenza
  • Administration
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2024 ∙ San Francisco Ramos, A. Liu Sanchez, C. Bovill Rose, T. Smith, D. Thorn, N. Galiza, E. Miah, T. Pearce, J. Hultin, C. Cosgrove, C. Hsia, Y. Heath, P. T.

Comparing reactogenicity of COVID-19 vaccine boosters: a systematic review and meta-analysis

  • All age groups
  • COVID-19
  • Safety
  • Administration
Methodological quality (AMSTAR 2):
Low
2024 ∙ Zeng, Y. Du, Z. Shao, C. Zhao, M.

Comprehensive insights into COVID-19 vaccine-associated multiple evanescent white dot syndrome (MEWDS): A systematic analysis of reported cases

  • Adolescents
  • Adults
  • Older adults
  • COVID-19
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2024 ∙ Chamani, I. J. Taylor, L. L. Dadoun, S. E. McKenzie, L. J. Detti, L. Ouellette, L. McCulloh, D. H. Licciardi, F. L.

Coronavirus Disease 2019 (COVID-19) Vaccination and Assisted Reproduction Outcomes: A Systematic Review and Meta-analysis

  • All age groups
  • COVID-19
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2024 ∙ Gharpure, R. Chard, A. N. Cabrera Escobar, M. Zhou, W. Valleau, M. M. Yau, T. S. Bresee, J. S. Azziz-Baumgartner, E. Pallas, S. W. Lafond, K. E.

Costs and cost-effectiveness of influenza illness and vaccination in low- and middle-income countries: A systematic review from 2012 to 2022

  • Children
  • Older adults
  • Pregnant women
  • Low and Middle Income Countries
  • Influenza
  • Economic aspects
Methodological quality (AMSTAR 2):
Not applicable
Loading...